3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[f]indol-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[f]indol-2-one
• 英文别名: 3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydrobenzo[f]indol-2-one
• 化学式: C₁₈H₁₂ClNO₂
• 分子量: 309.752
• InChiKey: PDQZBWKUIMWHDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Methods for treating hyperactive gastric motility
  申请人：Wyeth

  公开号：US20020183395A1

  公开（公告）日：2002-12-05

  This invention provides methods and pharmaceutical compositions for treating, inhibiting or preventing hyperactive gastric motility in a mammal utilizing agonists of KCNQ potassium channels, including KCNQ2, KCNQ3, KCNQ4 and KCNQ5 potassium channels, alone or in combination. The hyperactive gastric motility may be associated with maladies including, colitis, irritable bowel syndrome and Crohn's disease. Compounds useful in these methods include the 1,2,4-triamino-benzene derivatives described in U.S. Pat. No. 5,384,330 (Dieter et al.) and the substituted 3-phenyl oxindole compounds described in U.S. Pat. No. 5,565,483 (Hewawasam et al.). Among the preferred compounds of this invention is N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, also referred to as retigabine.

  这项发明提供了治疗、抑制或预防哺乳动物胃动力亢进的方法和药物组合，利用KCNQ钾通道的激动剂，包括KCNQ2、KCNQ3、KCNQ4和KCNQ5钾通道，单独或组合使用。胃动力亢进可能与疾病有关，包括结肠炎、肠易激综合征和克罗恩病。这些方法中有用的化合物包括美国专利号5,384,330（Dieter等人）中描述的1,2,4-三氨基苯衍生物和美国专利号5,565,483（Hewawasam等人）中描述的取代3-苯基恩哌啶化合物。这项发明的首选化合物之一是N-[2-氨基-4-(4-氟苯基氨基)苯基]碳酸乙酯，也称为雷替加宾。
• Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
  申请人：——

  公开号：US20030181507A1

  公开（公告）日：2003-09-25

  The present invention relates to a novel method of treating of pain or anxiety, using compounds that modulate KCNQ potassium channels and currents. 1

  本发明涉及一种治疗疼痛或焦虑的新方法，使用调节KCNQ钾通道和电流的化合物。
• Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators
  申请人：NEUROSEARCH A/S

  公开号：EP1634594A1

  公开（公告）日：2006-03-15

  The present invention relates to the use of substituted 3-phenyl oxindole derivatives as modulators of the potassium KCNQ channels, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith.

  本发明涉及取代的 3-苯基吲哚衍生物作为 KCNQ 钾通道调节剂的用途、包含这些化合物的药物组合物以及治疗方法。
• 3-Substituted oxindole derivatives as potassium channel modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0747354B1

  公开（公告）日：2000-08-16
• USE OF 3-SUBSTITUTED OXINDOLE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS
  申请人：NEUROSEARCH A/S

  公开号：EP1303269B1

  公开（公告）日：2005-12-07